natgillin/translations-raw huggingface dataset:
The educational materials will reinforce the warnings about the teratogenicity of mycophenolate, provide advice on contraception before therapy is started and guidance on the need for pregnancy testing. 
Izobraževalno gradivo bo okrepilo opozorila o teratogenosti mofetilmikofenolata, zagotovilo nasvet glede kontracepcije pred začetkom zdravljenja in dalo navodila glede potrebe po testiranju nosečnosti.
Reports of overdoses with mycophenolate mofetil have been received from clinical trials and during post-marketing experience. 
O primerih prevelikega odmerjanja mofetilmikofenolata so poročali v kliničnih preskušanjih in med trženjem zdravila.
Blood and immune system 
Krvni in imunski sistem
• Advice on action if a pregnancy occurs or is suspected during or shortly after being treated with mycophenolate mofetil. 
Nasvet o postopku, če se nosečnost pojavi (ali sumi nanjo) med ali kmalu po zdravljenju z mofetilmikofenolatom.
Pregnancy whilst taking mycophenolate must be avoided. 
V času jemanja mikofenolata se je treba izogniti nosečnosti.
• sinus problems. 
• težave s sinusi.
In addition, the text relating to women should explain the pregnancy test requirements prior to and during therapy with mycophenolate mofetil; including the advice for two negative pregnancy tests prior to starting therapy and the importance of the timing of these tests. 
Dodatno morajo biti v besedilu za bolnice pojasnjene zahteve po testiranju nosečnosti pred in med zdravljenjem z mofetilmikofenolatom, vključno z nasveti za dva negativna testa nosečnosti pred začetkom zdravljenja in pomembnostjo časovne razporeditve teh testov.
It is expected that an overdose of mycophenolate mofetil could possibly result in oversuppression of the immune system and increase susceptibility to infections and bone marrow suppression (see section 4.4). 
Pričakuje se, da bi preveliko odmerjanje mofetilmikofenolata lahko povzročilo čezmerno supresijo imunskega sistema in povečalo dovzetnost za okužbe in supresijo kostnega mozga (glejte poglavje 4.4).
Hypersensitivity reactions, including angioneurotic oedema and anaphylactic reaction have been reported. 
Poročali so o preobčutljivostnih reakcijah, vključno z angionevrotičnim edemom in anafilaktično reakcijo.
In the early post-transplant period (< 40 days post-transplant), renal, cardiac and hepatic transplant patients had mean MPA AUCs approximately 30 % lower and Cmax approximately 40 % lower compared to the late post-transplant period (3-6 months post-transplant). 
V zgodnjem obdobju po presaditvi (do 40. dneva po presaditvi) je srednja AUC mikofenolne kisline pri bolnikih z ledvičnim, srčnim ali jetrnim presadkom za približno 30 % manjša, Cmax pa za približno 40 % manjša v primerjavi s poznejšim obdobjem po presaditvi (3 do 6 mesecev po presaditvi).
Male patients of reproductive potential should be made aware of and discuss the potential risk of fathering a child with a qualified health-care professional. 
Bolniki, ki lahko spočnejo otroka, se morajo zavedati možnih tveganj spočetja med zdravljenjem in se o njih pogovoriti z usposobljenim zdravstvenim delavcem.
Mycophenolate is a powerful human teratogen. 
Mofetilmikofenolat je močan humani teratogen.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist. 
Če imate dodatna vprašanja o uporabi tega zdravila, se posvetujte s svojim zdravnikom ali farmacevtom.
Two genotoxicity assays (in vitro mouse lymphoma assay and in vivo mouse bone marrow micronucleus test) showed a potential of mycophenolate mofetil to cause chromosomal aberrations. 
Dve študiji genotoksičnosti (in vitro mišji limfomski preskus ter in vivo mišji mikronukleosni test kostnega mozga) sta pokazali, da lahko mofetilmikofenolat povzroči prelome kromosomov.
Patients taking oral contraceptives 
Bolnice, ki jemljejo peroralne kontraceptive
Do not open or crush the capsules and breathe the powder inside the capsules or allow it to touch your skin. 
Ne odpiraje ali drobite kapsul, ne vdihujte prahu, ki je v kapsulah in ne dovolite, da pride prah v stik s kožo.
Pregnancy, contraception and breast-feeding 
Nosečnost, kontracepcija in dojenje
Trimethoprim/sulfamethoxazole No effect on the bioavailability of MPA was observed. 
Trimetoprim/sulfametoksazol Vplivov na biološko uporabnost mikofenolne kisline niso opazili.
Do not take Myclausen 
Ne jemljite zdravila Myclausen
Do not break or crush the tablets. 
Tablet ne lomite in jih ne drobite.
Additional amendments have been made regarding use of contraception in women and pregnancy testing, to clarify the requirements. 
Za pojasnitev zahtev so bile dodane spremembe glede uporabe kontracepcije pri bolnicah in testov nosečnosti.
Most (about 87 %) of the administered dose is excreted in the urine as MPAG. 
Večina (87 %) zaužitega odmerka se je izločila v urin v obliki mikofenolglukuronida.
It will be explained that the correct course of action, based on an assessment of the individual benefit-risk, will be determined on a case by case basis through a discussion between the treating physician and the patient. 
Razloženo bo, da bo v pogovoru med zdravnikom in bolnico določeno pravilno soslednje dogodkov glede na oceno razmerja med koristjo in tveganjem za posamezen primer.
Oral Myclausen should be initiated within 72 hours following transplantation. 
Peroralno dajanje zdravila Myclausen je treba uvesti v 72 urah po presaditvi.
Each carton contains either 50 or 150 tablets. 
Vsaka škatla vsebuje 50 ali 150 tablet.
OTHER SPECIAL WARNING(S), IF NECESSARY Myclausen film-coated tablets should be handled with care. 
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA Filmsko obložene tablete Myclausen je treba uporabljati previdno.
Because of robust clinical evidence showing a high risk of abortion and congenital malformations when mycophenolate mofetil is used in pregnancy every effort to avoid pregnancy during treatment should be taken. 
Zaradi zanesljivih kliničnih dokazov, ki kažejo na visoko tveganje za splav in kongenitalne malformacije, če se mofetilmikofenolat uporablja v nosečnosti, je treba poskrbeti za ukrepe, da se izognemo nosečnosti med zdravljenjem.
Serum levels of LH, FSH and progesterone were not significantly affected. 
Koncentracije LH, FSH in progesterona v serumu niso bile pomembno spremenjene.
PRCA may resolve with dose reduction or cessation of Myclausen therapy. 
PRCA je lahko reverzibilna z zmanjšanjem odmerka ali s prekinitvijo zdravljenja z zdravilom Myclausen.
Because mycophenolate mofetil has demonstrated teratogenic effects in rats and rabbits, Myclausen capsules should not be opened or crushed to avoid inhalation or direct contact with skin or mucous membranes of the powder contained in Myclausen capsules. 
Ker ima mofetilmikofenolat dokazane teratogene učinke pri podganah in kuncih, kapsul Myclausen ne smemo odpreti ali drobiti, da se izognemo vdihavanju ali neposrednemu stiku praška v Myclausen kapsulah s kožo ali sluznico.
If you forget to take Myclausen 
Če ste pozabili vzeti zdravilo Myclausen
Separate guides for healthcare professionals and patients should be provided. 
Pripraviti je treba poseben vodnik za zdravstvene delavce in poseben vodnik za bolnike.
White oblong capsules. 
Bele podolgovate kapsule
Myclausen is used to prevent your body rejecting a transplanted organ. 
Zdravilo Myclausen prepreči, da bi vaše telo zavrnilo presadek.
OTHER SPECIAL WARNING(S), IF NECESSARY Myclausen capsules should be handled with care. 
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA Myclausen kapsule je treba uporabljati previdno.
Children may be more likely than adults to have some side effects. 
Nekatere neželene učinke imajo otroci pogosteje kot odrasli.
Each carton contains either 50 or 150 film-coated tablets. 
Vsaka škatla vsebuje 50 ali 150 filmsko obloženih tablet.
The nonclinical toxicity profile of mycophenolate mofetil appears to be consistent with adverse events observed in human clinical trials which now provide safety data of more relevance to the patient population (see section 4.8). 
Neklinični profil toksičnosti mofetilmikofenolata je v skladu z neželenimi učinki, ki so jih opazili pri kliničnih študijah pri ljudeh, ki so z varnostnega vidika pomembnejši (glej poglavje 4.8).
If you are a woman who could become pregnant, you must provide a negative pregnancy test before starting treatment and must follow the contraception advice given to you by your doctor. 
Če ste bolnica, ki bi lahko zanosila, morate pred začetkom zdravljenja zagotoviti negativen test nosečnosti in slediti nasvetom za kontracepcijo, ki vam jih je dal vaš zdravnik.
It is not known if MPA is present in semen. 
Ni znano, ali je mofetilmikofenolat prisoten v semenu.
If such contact occurs, wash thoroughly with soap and water; rinse eyes with plain water. 
Če pride do stika s praškom, je potrebno temeljito izpiranje z vodo in milom, oči izpiramo le z vodo.
What Myclausen looks like and contents of the pack 
Izgled zdravila Myclausen in vsebina pakiranja
Passauer Pharma GmbH Eiderstedter Weg 3 14129 Berlin Germany 
Passauer Pharma GmbH Eiderstedter Weg 3 14129 Berlin Nemčija
• Do not break or crush them. 
• Ne smete jih lomiti ali drobiti.
In renal transplant patients with severe chronic renal impairment (glomerular filtration rate < 25 mL/min/1.73 m2), outside the immediate post-transplant period, doses greater than 1 g administered twice a day should be avoided. 
Ledvična okvara Bolnikom s hudo kronično ledvično okvaro (glomerulna filtracija < 25 ml/min/1,73 m2) izven obdobja neposredno po presaditvi ne dajemo odmerkov, večjih od 1 g dvakrat na dan.
White round film-coated tablets. 
Bele okrogle filmsko obložene tablete
This include serious allergic reactions (such as anaphylaxis, angioeodema), fever, feeling very tired, difficulty in sleeping, pains (such as stomach, chest, joint or muscle, pain on passing urine), headache, flu symptoms and swelling. 
Ti vključujejo resne alergijske reakcije (kot sta anafilaksa, angioedem), povišano telesno temperaturo, močno utrujenost, motnje spanca, bolečine (bolečino v želodcu, bolečino v prsih, bolečino v sklepih ali mišicah, bolečino pri uriniranju), glavobol, gripi podobne simptome in otekline.
Talk to your doctor straight away before taking Myclausen: 
Nemudoma se posvetujte s svojim zdravnikom, preden vzamete zdravilo Myclausen:
Paediatric population aged 2 to 18 years The recommended dose of mycophenolate mofetil is 600 mg/m administered orally twice daily (up to a maximum of 2 g daily). 
Pediatrični bolniki stari od 2 do 18 let Priporočeni odmerek mofetilmikofenolata je 600 mg/m2, peroralno dvakrat na dan (do največ 2 g na dan).
Patients treated with immunosuppressants, including Myclausen, are at increased risk for opportunistic infections (bacterial, fungal, viral and protozoal), fatal infections and sepsis (see section 4.8). 
Bolniki, ki se zdravijo z imunosupresivi, vključno z zdravilom Myclausen, imajo povečano tveganje za oportunistične okužbe (bakterijske, glivične, virusne in protozojske), smrtne okužbe in sepso (glejte poglavje 4.8).
The change in predose level may not accurately represent changes in overall MPA exposure. 
Spremembe koncentracije pred naslednjim odmerkom morda niso točen pokazatelj sprememb v celokupni izpostavljenosti mikofenolni kislini.
These data support extrapolation of this finding to all antacids because the reduction in exposure when mycophenolate mofetil was co- administered with magnesium and aluminium hydroxides is considerably less than when mycophenolate mofetil was co-administered with PPIs. 
Ti podatki podpirajo ekstrapolacijo teh ugotovitev na vse antacide, saj je zmanjšanje izpostavljenosti, kadar je zdravilo mofetilmikofenolata sočasno uporabljeno z magnezijevimi in aluminijevi hidroksidi, občutno manjše v primerjavi s sočasno uporabo zdravila mofetilmikofenolata in zaviralcev protonske črpalke.
Contraception in women taking Myclausen If you are a woman who could become pregnant you must use an effective methods of contraception with Myclausen. 
Kontracepcija pri bolnicah, ki jemljejo zdravilo Myclausen Če ste bolnica, ki bi lahko zanosila, morate med zdravljenjem z zdravilom Myclausen uporabljati učinkovito kontracepcijsko zaščito, in sicer:
Therefore, the following precautionary measures are recommended: sexually active male patients or their female partners are recommended to use reliable contraception during treatment of the male patient and for at least 90 days after cessation of mycophenolate mofetil. 
Zato so priporočljivi naslednji previdnostni ukrepi: priporočljivo je, da med bolnikovim zdravljenjem z mofetilmikofenolatom in še vsaj 90 dni po prenehanju zdravljenja spolno aktivni bolniki ali njihove partnerke uporabljajo zanesljivo kontracepcijo.
Gastrointestinal effects were observed in the dog at systemic exposure levels equivalent to or less than the clinical exposure at the recommended dose. 
Pri psih so se pojavili gastrointestinalni neželeni učinki pri sistemski izpostavljenosti, ki je bila enaka ali manjša od klinične izpostavljenosti pri priporočenem odmerjanju.
Each carton contains either 100 or 300 capsules. 
Vsaka škatla vsebuje 100 ali 300 kapsul.
Mycophenolate mofetil is an IMPDH (inosine monophosphate dehydrogenase) inhibitor. 
Mofetilmikofenolat je zaviralec inozin-monofosfat-dehidrogenaze (IMPDH).
Some of the more usual problems are diarrhoea, fewer white cells or red cells in your blood, infection and vomiting. 
Pogostejše težave so driska, zmanjšano število belih ali rdečih krvničk v krvi, okužbe in bruhanje.
Take care not to let any powder from inside a broken capsule get onto your skin. 
Bodite previdni, da prašek, ki ga vsebujejo poškodovane kapsule, ne pride v stik s kožo.
If you take more Myclausen than you should 
Če ste vzeli večji odmerek zdravila Myclausen, kot bi smeli
It is recommended that patients who develop persistent pulmonary symptoms, such as cough and dyspnoea, are investigated. 
Bolnike, pri katerih pulmonalni simptomi, kot sta kašelj in dispneja, vztrajajo, je priporočljivo pregledati.
Mycophenolate mofetil has been shown to be excreted in the milk of lactating rats. 
Študije na podganah so pokazale, da se mofetilmikofenolat izloča v mleko podgan v laktaciji.
Based on the results of a single dose administration study of recommended doses of oral mycophenolate and IV ganciclovir and the known effects of renal impairment on the pharmacokinetics of mycophenolate mofetil (see section 4.2) and ganciclovir, it is anticipated that co-administration of these agents (which compete for mechanisms of renal tubular secretion) will result in increases in MPAG and ganciclovir concentration. 
Na podlagi rezultatov študije enkratnega odmerjanja priporočenih odmerkov peroralne oblike mofetilmikofenolata in intravenske oblike ganciklovirja in znanih učinkov ledvične okvare na farmakokinetiko mofetilmikofenolata (glejte poglavje 4.2) in ganciklovirja, je pričakovati, da bo sočasno dajanje obeh učinkovin, ki tekmujeta v mehanizmih renalne tubularne sekrecije, povzročilo povečanje koncentracij mikofenolglukuronida in ganciklovirja.
Patients should be advised that during treatment with Myclausen, vaccinations may be less effective, and the use of live attenuated vaccines should be avoided (see section 4.5). 
Bolnike, ki prejemajo zdravilo Myclausen, moramo opozoriti, da so lahko cepiva manj učinkovita, uporabi živih cepiv pa se morajo izogibati (glejte poglavje 4.5).
• Based on literature reports, malformations occurred in 23 to 27% of live births in women exposed to mycophenolate mofetil during pregnancy (compared to 2 to 3 % of live births in the overall population and approximately 4 to 5% of live births in solid organ transplant recipients treated with immunosuppressants other than mycophenolate mofetil). 
V literaturnih poročilih so se malformacije pojavljale pri 23 do 27 % živorojenih otrok bolnic, ki so bile med nosečnostjo izpostavljene mofetilmikofenolatu, (v primerjavi z 2 do 3 % pri živorojenih otrocih v celokupni populaciji ter približno 4 do 5 % pri živorojenih otrocih bolnic s presajenim solidnim organom, zdravljenih z drugimi imunosupresivi razen mofetilmikofenolata).
Congenital disorders 
Kongenitalne okvare
1 What Myclausen is and what it is used for 2 What you need to know before you take Myclausen 3 How to take Myclausen 4 Possible side effects 
Kaj je zdravilo Myclausen in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Myclausen Kako jemati zdravilo Myclausen Možni neželeni učinki
As a result of enterohepatic recirculation, secondary increases in plasma MPA concentration are usually observed at approximately 6-12 hours post-dose. 
Zaradi enterohepatičnega ponovnega obtoka se plazemske koncentracije mikofenolne kisline 6 do12 ur po odmerku ponovno zvečajo.
PHARMACEUTICAL FORM AND CONTENTS 100 hard capsules 
FARMACEVTSKA OBLIKA IN VSEBINA 100 trdih kapsul
If you do become pregnant during the treatment with mycophenolate, you must inform your doctor immediately. 
Če med zdravljenjem z mofetilmikofenolatom zanosite, morate nemudoma obvestiti zdravnika.
In a female fertility and reproduction study conducted in rats, oral doses of 4.5 mg/kg/day caused malformations (including anophthalmia, agnathia, and hydrocephaly) in the first generation offspring in the absence of maternal toxicity. 
V študijah plodnosti in reproduktivnosti so peroralni odmerki po 4,5 mg/kg/dan pri podganjih samicah povzročili malformacije (vključno z anoftalmijo, agnatijo in hidrocefalijo) pri prvi generaciji potomcev, pri materah pa škodljivih učinkov ni bilo.
When comparing rates of transplant rejection, rates of graft loss or adverse event profiles between mycophenolate mofetil patients with and without concomitant telmisartan medication, no clinical consequences of the pharmacokinetic medicinal product-medicinal product interaction were seen. 
Ko so primerjali deleže zavrnitve presadka, deleže izgube presadka ali profile neželenih učinkov med bolniki, zdravljenimi z mofetilmikofenolatom v kombinaciji s telmisartanom ali brez njega, niso opazili nobenih kliničnih posledic farmakokinetičnega medsebojnega delovanja med zdraviloma.
PHARMACEUTICAL FORM AND CONTENTS 50 film-coated tablets 
FARMACEVTSKA OBLIKA IN VSEBINA 50 filmsko obloženih tablet
No substantial alteration of MPA pharmacokinetics is anticipated and Myclausen dose adjustment is not required. 
Znatnih sprememb v farmakokinetiki mikofenolne kisline ni pričakovati, zato prilagajanje odmerkov zdravila Myclausen ni potrebno.
Capsule shells: gelatine, titanium dioxide (E 171) 
Obloga kapsul: želatina, titanov dioksid (E 171).
Titanium dioxide (E 171) 
Obloga kapsul želatina titanov dioksid (E 171)
Gingival hyperplasia (≥ 1/100 to < 1/10), colitis including cytomegalovirus colitis, (≥ 1/100 to < 1/10), pancreatitis (≥ 1/100 to < 1/10) and intestinal villous atrophy. 
Gingivalna hiperplazija (≥ 1/100 do < 1/10), kolitis, vključno s kolitisom, ki ga povzroča citomegalovirus (≥ 1/100 do < 1/10), pankreatitis (≥ 1/100 do < 1/10) in atrofija črevesne sluznice.
PHARMACEUTICAL FORM AND CONTENTS 150 film-coated tablets 
FARMACEVTSKA OBLIKA IN VSEBINA 150 filmsko obloženih tablet
There are no data on mycophenolate mofetil with phosphate binders other than sevelamer. 
Ni podatkov o dajanju mofetilmikofenolata z drugimi vezalci fosfatov, razen sevelamerjem.
As a precaution you or your female partner are recommended to use reliable contraception during treatment and for 90 days after you stop taking Myclausen. 
Kot previdnostni ukrep je za vas ali vašo partnerko priporočljivo, da med zdravljenjem in 90 dni po končanem zdravljenju uporabljate/uporablja zanesljivo obliko kontracepcije.
AcMPAG is pharmacologically active and is suspected to be responsible for some of mycophenolate mofetil´s side effects (diarrhoea, leucopenia). 
Ta je farmakološko aktiven in verjetno odgovoren za nekaj neželenih učinkov mofetilmikofenolata (diareja, levkopenija).
Pharmacokinetic behaviour of mycophenolate mofetil in the elderly ( 65 years) has not been formally evaluated. 
Farmakokinetičnih parametrov mofetilmikofenolata pri starejših bolnikih (starih 65 let ali več) niso proučevali.
Because of the potential for serious adverse reactions to mycophenolate mofetil in breast-fed infants, Myclausen is contraindicated in nursing mothers (see section 4.3). 
Zaradi možnih resnih škodljivih vplivov mofetilmikofenolata na dojenčke, je zdravilo Myclausen pri doječih materah kontraindicirano (glejte poglavje 4.3).
As some adverse reactions occur with greater frequency in this age group (see section 4.8) compared with adults, temporary dose reduction or interruption may be required; these will need to take into account relevant clinical factors including severity of reaction. 
V tej starostni skupini se v primerjavi z odraslimi bolniki nekateri neželeni učinki pojavljajo pogosteje (glejte poglavje 4.8), zato bo morda treba začasno zmanjšati odmerek ali prekiniti zdravljenje.
No effects on fertility or reproductive parameters were evident in the dams or in the subsequent generation. 
Pri samicah in nadaljnjih generacijah potomcev niso opazili učinkov na reproduktivnost ali plodnost.
5 How to store Myclausen 6 Contents of the pack and other information 
Shranjevanje zdravila Myclausen Vsebina pakiranja in dodatne informacije
• Counselling of patients: This section will emphasise the importance of a thorough, informative and ongoing dialogue between patient and healthcare professional about the pregnancy risks associated with mycophenolate mofetil and the relevant minimisation strategies including alternative treatment choices, if applicable. 
To poglavje bo poudarilo pomembnost temeljitega, poučnega in stalnega pogovora med bolnikom in zdravstvenim delavcem o tveganju uporabe mofetilmikofenolata med nosečnostjo in ustreznih strategijah za njegovo zmanjševanje, vključno z drugimi možnostmi zdravljenja, če so primerne.
Myclausen capsules at a dose of 750 mg twice daily (1.5 g daily dose). 
Myclausen v odmerku 750 mg dvakrat dnevno (dnevni odmerek 1,5 g).
This includes infections of the brain, skin, mouth, stomach and gut, lungs and urinary system. 
Pogostejše so okužbe možganov, kože, ust, želodca in črevesja, pljuč ter sečil.
Very common Common Hepatic enzyme increased, blood creatinine increased, blood lactate dehydrogenase increased, blood urea increased, blood alkaline phosphatase increased, weight decreased Note: 501 (2 g mycophenolate mofetil daily), 289 (3 g mycophenolate mofetil daily) and 277 (2 g intravenous / 3 g oral mycophenolate mofetil daily) patients were treated in Phase III studies for the prevention of rejection in renal, cardiac and hepatic transplantation, respectively. 
Preiskave zelo pogosti pogosti zvišani jetrni encimi, zvišan kreatinin v krvi, zvišana laktat-dehidrogenaza v krvi, zvišana sečnina v krvi, zvišana alkalna fosfataza v krvi, zmanjšana telesna teža Opomba: 501 (2 g mofetilmikofenolata dnevno), 289 (3 g mofetilmikofenolata dnevno) in 277 (2 g intravenozno / 3 g mofetilmikofenolata peroralno dnevno) bolnikov je bilo zdravljenih v III. fazi kliničnih preiskušanj za preprečitev zavrnitve ledvičnega, srčnega oziroma jetrnega presadka.
• Spontaneous abortions have been reported in 45 to 49% of pregnant women exposed to mycophenolate mofetil, compared to a reported rate of between 12 and 33% in solid organ transplant patients treated with immunosuppressants other than mycophenolate mofetil. 
Pri nosečnicah, izpostavljenih mofetilmikofenolatu, so poročali o spontanih splavih pri 45 do 49 % bolnic v primerjavi z med 12 in 33 % pri bolnicah s presajenim solidnim organom, zdravljenih z drugimi imunosupresivi razen mofetilmikofenolata.
• The first dose will be given within 3 days after the transplant operation. 
• Prvi odmerek prejmete v 3 dneh po presaditvenem posegu.
INFORMATION IN BRAILLE Myclausen 500 mg 
PODATKI V BRAILLOVI PISAVI Myclausen 500 mg
If you stop taking Myclausen 
Če ste prenehali jemati zdravilo Myclausen
PHARMACEUTICAL FORM Film-coated tablet White round film-coated tablets. 
FARMACEVTSKA OBLIKA Filmsko obložena tableta Bele okrogle filmsko obložene tablete
In volunteers with alcoholic cirrhosis, hepatic MPA glucuronidation processes were relatively unaffected by hepatic parenchymal disease. 
Pri prostovoljcih z alkoholno jetrno cirozo procesi glukuronidacije mikofenolne kisline v jetrih niso bili pomembno spremenjeni zaradi bolezni jetrnega parenhima.